IMPACT Therapeutics (IMPACT), a PRC-based synthetic-lethality oncology specialist, reported interim results for the six months ended 30 June 2026 that show rapid commercial traction for its PARP inhibitor senaparib and a strengthened balance sheet following the company’s May Hong Kong IPO.
Financial Performance • Revenue jumped 316.8% year-on-year to RMB105.19 million, driven by a steep rise in senaparib sales to RMB70.35 million (66.9% of total revenue) and licensing income of RMB34.84 million. • Gross profit expanded to RMB95.48 million, translating into a 90.8% gross margin versus 97.7% a year earlier. • R&D expenditure increased 13.1% to RMB97.64 million as clinical and pre-clinical programmes advanced. • Administrative costs reached RMB50.30 million, up 72.3%, reflecting IPO-related expenses. • Net loss narrowed 29.5% to RMB90.81 million; non-HKFRS adjusted net loss fell 62.6% to RMB20.87 million. • Net assets turned positive at RMB775.77 million, versus a deficit of RMB957.89 million at 2025 year-end. • Cash, cash equivalents, time deposits and short-term investments totalled RMB1.07 billion, supported by HK$879 million in IPO proceeds and the full exercise of the over-allotment option.
Commercial Highlights • Following National Reimbursement Drug List inclusion effective 1 January 2026, senaparib achieved nationwide hospital and pharmacy coverage and is now available in all mainland provinces, over 380 pharmacies and nearly 1,200 medical institutions. • Senaparib’s first-line maintenance indication for ovarian cancer has been incorporated into multiple 2025 Chinese oncology guidelines.
Pipeline & Business Development • Senaparib: EMA accepted the MAA for first-line ovarian cancer maintenance; updated Phase 3 FLAMES progression-free survival data will be presented at ESMO 2026. • IMP1734 (PARP1-selective inhibitor): Phase 1/2 data showcased at ASCO 2026; additional results across monotherapy and combination cohorts accepted for ESMO 2026. • IMP9064 (ATR inhibitor): Initial combination data with senaparib in PARP-experienced ovarian cancer showed early tumour shrinkage with no Grade ≥3 adverse events. • IMP1707 (CNS-penetrant PARP1-selective inhibitor): First-in-human results to be presented at ESMO 2026. • Pre-clinical additions include IMP3201, a CEACAM5 dual-payload ADC, and IMP2794, a KAT6A PROTAC degrader. • July 2026: Exclusive licensing pact with Pharmanovia grants rights to senaparib across 66 countries in Europe, MENA, Australia and New Zealand. IMPACT is eligible for up to €423.5 million in upfront, regulatory and commercial milestones plus tiered mid-twenties royalties.
Capital Allocation IPO proceeds are earmarked for (i) global development and commercial expansion of senaparib (51% of funds), (ii) advancement of key assets IMP1734 and IMP9064 (31%), (iii) other pipeline programmes (8%), (iv) platform R&D (8%) and (v) working capital and corporate purposes (2%). As of 30 June 2026, 6.5% of the HK$879 million raised had been deployed.
Outlook Management will focus on scaling senaparib’s China uptake, progressing global regulatory filings, and accelerating clinical development of its differentiated synthetic-lethality pipeline while leveraging partnerships to unlock overseas markets.